Contains content in memory of Professor Amit Patel, RIP 2021. Please note, Professor Patel held the title of Doctor at the time of filming

Optimising Care For Patients With High-Risk AML – BSH Symposia 2021

Dr Amit Patel chairs the panel alongside Prof. Thomas Cluzeau and Dr Sree Munisamy. In the Symposium, Dr Patel will define high-risk AML, while providing a background to the breakthrough trials of Vyxeos Liposomal. Prof. Cluzeau presents the case study of a 69-year-old French woman, in addition to describing the real-world evidence of Vyxeos Liposomal in French and Italian centres. Finally, Dr Munisamy will review the Q-TWiST (QoL) study in the context of the case study of a 69-year-old British woman who contracted COVID-19 during the course of her treatment.

Prescribing Information can be found at the top of this page. Adverse event reporting is available at the bottom of this page.

Topics: Cytogenetics Quality of Life Real-world Data Safety Vyxeos Liposomal Data


Adverse events should be reported. Reporting forms and information for the UK can be found at

For Ireland, reporting forms and information can be found at:

Adverse events should also be reported to Jazz Pharmaceuticals at

UK-VYX-2100137 | February 2022